Quetiapine (50 mg/day-100mg/day)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Bowel Disorders
Conditions
Functional Bowel Disorders
Trial Timeline
Feb 1, 2008 → May 1, 2012
NCT ID
NCT00617396About Quetiapine (50 mg/day-100mg/day)
Quetiapine (50 mg/day-100mg/day) is a pre-clinical stage product being developed by AstraZeneca for Functional Bowel Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00617396. Target conditions include Functional Bowel Disorders.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00617396 | Pre-clinical | Completed |
Competing Products
20 competing products in Functional Bowel Disorders